Bristol-Myers Squibb Q2 FY2026 Earnings Call Summary
BMY
NYSE
Healthcare
📅 2026-07-30
⏱ ~60 sec read
🟢 Bullish
⏱️ 60-Second Brief
Bristol-Myers Squibb · Q2 FY2026
Stock Next Day
▲ 0.69%
$64.86 → $65.31
Revenue
$.B
EPS
$6.05
AI Sentiment
🟢 Bullish
The company demonstrated strong growth in its key "Growth Po…
📌 Bottom Line:
Bristol Myers Squibb reported strong second-quarter results driven by its Growth Portfolio, leading the company to raise its full-year revenue and non-GAAP EPS guidance. This performance underscores the successful execut…
🤖 AI-Assisted Summary — Produced using a custom AI pipeline by Abhi, reviewed for accuracy.
·
⚠️ Not financial advice. For informational purposes only.
Full Disclaimer →
📋 TL;DR — What Happened
Bristol Myers Squibb reported strong second-quarter results driven by its Growth Portfolio, leading the company to raise its full-year revenue and non-GAAP EPS guidance. This performance underscores the successful execution of its strategy to build long-term value through innovative medicines and pipeline advancements.
📊 Key Financial Metrics
Revenue
$.B
EPS (Diluted)
$6.05
AI Sentiment
🟢 Bullish
The company demonstrated strong growth in its key "Growth Portfolio," significantly raised its full-year financial guidance for both revenue and non-GAAP EPS, and showcased a robust pipeline with multiple regulatory successes and strategic investments in future innovation.
✅ What Went Well
**Exceptional Growth Portfolio Momentum:** The Growth Portfolio delivered a 15% increase in revenues, reaching $7.6 billion, driven by key products such as Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, and Opdualag, which are expanding their market share and contributing significantly to the company's top line.
**Strong Overall Revenue Growth:** Total revenues for the second quarter increased by a solid 6% (5% Ex-FX) to $13.0 billion, surpassing previous year's performance and indicating healthy demand across the company's product offerings, particularly in the U.S. market which saw a 6% increase to $9.0 billion.
**Significant Uplift in Full-Year Guidance:** Management raised its 2026 full-year revenue guidance by approximately $3.0 billion at the midpoint, now expecting $49.0 billion to $50.0 billion, and increased non-GAAP EPS guidance to $6.75 to $7.00, signaling strong confidence in sustained operational execution and future profitability.
**Key Pipeline Advancements and Regulatory Successes:** The quarter saw several crucial regulatory milestones, including the FDA's acceptance of sBLA for Reblozyl and NDA for mezigdomide (with PDUFA dates in 2027), priority review for Camzyos, and European Commission approvals for Opdivo in Hodgkin Lymphoma and Sotyktu for psoriatic arthritis, reinforcing the strength and breadth of the company's development pipeline.
**Strategic Technology and R&D Collaborations:** Bristol Myers Squibb is proactively investing in future growth through strategic partnerships, notably expanding its collaboration with NVIDIA for AI infrastructure and deploying Anthropic's Claude for enterprise-wide intelligence, alongside a global strategic collaboration with Hengrui Pharma to advance 13 early-stage programs in oncology, hematology, and immunology, positioning the company for long-term innovation.
**Robust Eliquis Performance:** Worldwide Eliquis revenues are now projected to increase by 20%-25% in 2026 compared to 2025, an upward revision from the prior guidance of 10%-15%, demonstrating continued strong demand for this key product despite its maturity.
⚠️ Concerns & Risks
**Continued Decline in Legacy Portfolio:** Revenues from the Legacy Portfolio decreased by 4% (5% Ex-FX) to $5.4 billion, primarily due to the expected impact of generic competition on key products like Revlimid, Pomalyst/Imnovid, and Sprycel, indicating an ongoing challenge to manage the erosion of older revenue streams.
**Gross Margin Contraction:** The company experienced a 120 basis point decrease in both GAAP and non-GAAP gross margin, falling to 71.3% and 71.4% respectively, primarily attributed to a change in product mix, which could signal pressure on profitability as newer, potentially lower-margin products gain share or as older, higher-margin products decline.
**Increased Operating Expenses:** Selling, general and administrative (SG&A) expenses increased by 7% (GAAP) and 8% (non-GAAP), driven by investments in new product launches. Research and development (R&D) expenses also rose by 15% (GAAP), partly due to the purchase of a priority review voucher and higher IPRD impairment charges, indicating higher costs associated with bringing new drugs to market and maintaining pipeline momentum.
**Impact of Royalty Income Expiry:** The "Other (income)/expense, net" line item was negatively affected by the expiry of royalty income on diabetes products at the end of 2025, transitioning from a positive contribution to a net expense on a GAAP basis, representing a loss of a previous revenue stream.
**Reliance on Non-GAAP Metrics:** While non-GAAP EPS showed strong growth, the GAAP EPS of $1.62 was significantly lower than the non-GAAP EPS of $2.04, highlighting substantial adjustments for items like acquired IPRD charges, amortization of acquired intangible assets, and other specified items. This reliance on non-GAAP figures can sometimes obscure the full financial picture for investors.
🔮 CEO / Management Guidance
Christopher Boerner, Ph.D., stated that as a result of consistent execution and continued momentum, the company is raising its 2026 full-year outlook. Bristol Myers Squibb now expects full-year non-GAAP revenue to be in the range of approximately $49.0 billion to $50.0 billion and non-GAAP EPS to be between $6.75 and $7.00. This updated guidance reflects broad-based and continuing momentum across the portfolio, despite an anticipated increase in operating expenses to $16.5 billion due to investments in key pipeline programs and new product launches.
💬 Key Quote
The Growth Portfolio continues to deliver, achieving 15% growth in the quarter, and represents an expanding share of our overall business. We are building from a position of strength and progressing a differentiated pipeline designed to generate long-term value. As a result of our consistent execution and continued momentum, we are raising our 2026 full-year outlook." — Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer
🏢 About Bristol-Myers Squibb
Bristol-Myers Squibb (BMY) is a publicly listed company on the NYSE exchange in the Healthcare sector. EarningsBloom tracks its quarterly earnings calls to provide free AI-generated summaries for investors.
📈 Want to act on this insight?
Topics:
Pharmaceuticals
Oncology
Biotechnology
Drug Development
Financial Guidance
Artificial Intelligence
Strategic Partnerships
Revenue Growth
EPS
Pipeline
📁 More from Bristol-Myers Squibb
View all earnings summaries for Bristol-Myers Squibb →